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Genetically engineered mouse models are powerful tools
for studying cancer genes and validating targets for can-
cer therapy. We previously used a mouse lymphoma
model to demonstrate that the translation initiation fac-
tor eIF4E is a potent oncogene in vivo. Using the same
model, we now show that the oncogenic activity of
eIF4E correlates with its ability to activate translation
and become phosphorylated on Ser 209. Furthermore,
constitutively activated MNK1, an eIF4E Ser 209 kinase,
promotes tumorigenesis in a manner similar to eIF4E,
and a dominant-negative MNK mutant inhibits the in
vivo proliferation of tumor cells driven by mutations
that deregulate translation. Phosphorylated eIF4E pro-
motes tumorigenesis primarily by suppressing apoptosis
and, accordingly, the anti-apoptotic protein Mcl-1 is one
target of both phospho-eIF4E and MNK1 that contributes
to tumor formation. Our results provide insight into how
eIF4E contributes to tumorigenesis and pinpoint a level
of translational control that may be suitable for thera-
peutic intervention.
Supplemental material is available at http://www.genesdev.org.
Received August 13, 2007; revised version accepted October
24, 2007.
Mutations that deregulate mRNA translation are com-
mon events in human cancers. For example, activation
of phosphoinositol-3 kinase (PI3K) or a AKT/PKB, or in-
activation of Pten, Tsc1, or Tsc2, increase translation of
a subset of mRNAs that influence cell survival (for re-
view, see Bilanges and Stokoe 2007). While each of these
lesions affects additional processes, enforced expression
of certain translation factors transforms rodent fibro-
blasts and promotes tumorigenesis (Lazaris-Karatzas et
al. 1990; Ruggero et al. 2004; Wendel et al. 2004). Simi-
larly, small molecules that target these pathways sup-
press protein translation and have anti-tumor effects
(Dilling et al. 1994; Wendel et al. 2004). Thus, deregula-
tion of translation is an important step in oncogenic
transformation and may contribute to tumor mainte-
nance.
Most protein translation involves assembly of the
eIF4F translation initiation complex on the 5 cap struc-
ture, followed by recruitment of ribosomal subunits and
their associated factors (for review, see Hay and Sonen-
berg 2004). The eukaryotic translation initiation factor
eIF4E contributes to the eIF4F complex, and its activity
is controlled by mammalian target of rapamycin (mTOR)
through phosphorylation of the eIF4E-binding proteins
(4E-BP). mTOR-mediated phosphorylation of 4E-BP lib-
erates eIF4E allowing it to enter the eIF4F complex. Al-
though eIF4E is a general translation factor, it preferen-
tially enhances translation of a subset of mRNAs with
complex 5 untranslated regions (UTRs). These include a
number of transformation-related and survival genes
(Rajasekhar et al. 2003; Mamane et al. 2007).
eIF4E is overexpressed in several tumors and has been
linked to patient prognosis (for review, see Ruggero and
Pandolfi 2003). Although the molecular basis underlying
these associations is unknown, eIF4E affects cancer-rel-
evant processes such as apoptosis (Polunovsky et al.
2000) and senescence (Ruggero et al. 2004), and acts as an
oncogene alone or in combination with c-Myc (Lazaris-
Karatzas et al. 1990; Ruggero et al. 2004; Wendel et al.
2004). Presumably, these functions reflect the ability of
eIF4E to affect translation although other eIF4E-related
functions may be required (Ruggero and Pandolfi 2003).
eIF4E is a target of PI3K and mitogen-activated protein
kinase (MAPK) signaling, and may act as a convergence
point for these pathways. Thus, the PI3K pathway leads
to enhanced eIF4E activity via release from the 4E-BPs
and ERK or p38/MAPK can increase phosphorylation of
eIF4E via MNK1/2 (Waskiewicz et al. 1997). However,
the biological significance of eIF4E phosphorylation and
its effect on translation is controversial (for review, see
Scheper and Proud 2002). In Drosophila eIF4E phos-
phorylation seems important for normal development
(Lachance et al. 2002); mice with deletions in both Mnk
kinases develop normally without detectable eIF4E
phosphorylation (Ueda et al. 2004).
We previously used adoptive transfer methods to show
that eIF4E is a potent oncogene in the Eµ-Myc transgenic
mouse lymphoma model, producing aggressive and drug
resistant tumors (Wendel et al. 2004). Here, we use the
same model to further study eIF4E promotes tumorigen-
esis, identifying a regulatory role for the MNK kinases
and one downstream effector, Mcl-1. These studies un-
derscore the importance of eIF4E phosphorylation during
oncogenesis, and identify a point of translational regula-
tion that is a potential therapeutic target.
Results and Discussion
We used previously characterized eIF4E mutants to
study its action during oncogenesis (Fig. 1A). The W56A
mutant cannot bind the 5 mRNA cap structure blocking
translation initiation and nuclear–cytoplasmic export;
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the W73F mutation affects incorporation into the eIF4F
translation initiation complex but not mRNA transport
(Marcotrigiano et al. 1997); the S209 mutations target a
conserved phosphorylation site for MNK1/2 kinases,
with the serine-to-alanine (S209A) mutation abolishing
phosphorylation and the serine-to-aspartic acid (S209D)
mutation resembling phosphorylated eIF4E (Waskiewicz
et al. 1997). These mutants were cloned into MSCV-
IRES-GFP, and their expression verified in 3T3 cells fol-
lowing retroviral transduction (Supplementary Fig. 1A–
C). All mutants were efficiently expressed, except
W73A, which may be more prone to proteasomal degra-
dation (Murata and Shimotohno 2006) (Supplementary
Fig. 1C).
We examined the ability of each eIF4E variant to co-
operate with c-Myc during lymphomagenesis using a
rapid adoptive transfer strategy as previously described
for wild-type eIF4E (Wendel et al. 2004). Retroviruses
encoding eIF4E or the various mutants were introduced
into hematopoietic stem cells (HSCs) and used to recon-
stitute irradiated syngeneic recipients (Supplementary
Fig. 2). These mice were monitored for lymphoma, and
the tumor cells were analyzed for GFP expression.
As expected, wild-type eIF4E markedly accelerated tu-
mor development (eIF4E vs. GFP: P < 0.0001) (Fig. 1B). By
contrast, tumors arising from Eµ-Myc transgenic HSCs
infected with the W56A or W73F alleles arose with a
latency that resembled controls (W56A vs. GFP: P = 0.56;
W73F vs. GFP: P = 0.46). Although only ∼25% the initial
stem/progenitor cells were infected (data not shown),
lymphomas arising from eIF4E-expressing HSCs were in-
variably GFP positive (Fig. 1B,C). HSCs infected with the
other vectors were infected at a similar efficiency, but
only 0%–22% of the resulting tumors were GFP positive,
indicating they were not advantageous in vivo (Fig.
1B,C). Since the W56A mutant is defective in cap-depen-
dent translation, these data imply that this function is
crucial for eIF4E-mediated oncogenesis. The data also
suggest that the mRNA transport functions are dispens-
able, although it remains possible that the reduced ex-
pression of the W73F mutant (also seen for the W73A
mutant) contributes to the defect (Supplementary Fig.
2C).
The most surprising results arose from mice reconsti-
tuted with cells expressing eIF4E mutants affecting the
MNK1/2 phosphorylation site. Mice reconstituted with
cells expressing the S209A mutant were defective at pro-
moting tumorigenesis (S209A vs. GFP: P = 0.24); by con-
trast, mice reconstituted with cells expressing the phos-
phomimetic S209D mutant displayed accelerated tumor
onset comparable with wild-type eIF4E (S209D vs. GFP:
P < 0.0001) (Fig. 1B). Seventy-five percent of the tumors
arising from HSCs transduced with the S209D mutant
were GFP positive, while only 28% of HSCs infected
with S209A gave rise to tumors expressing the GFP re-
porter (Fig. 1B). Apparently, eIF4E phosphorylation at
S209 of is important for oncogenicity.
If eIF4E phosphorylation at Ser 209 is essential for on-
cogenesis, then constitutively activated MNK kinases
might also be tumorigenic. We therefore examined the
ability of an activated (T332D) or kinase-dead (T2A2)
form of MNK1 (Waskiewicz et al. 1999) to promote
tumorigenesis in the Eµ-Myc system. Like eIF4E,
activated MNK1, but not the kinase-dead mutant, sub-
stantially accelerated lymphomagenesis (Mnk1 vs. GFP:
P < 0.0001) (Fig. 2A), producing lymphomas with a ma-
ture B cell phenotype (Supplementary Table 1; Wendel et
al. 2004). Both Mnk1- and eIF4E-expressing lymphomas
showed low levels of apoptosis relative to most control
tumors (Fig. 2B). Thus, MNK1 promotes tumor forma-
tion in a manner comparable with its substrate eIF4E.
Disruption of apoptosis is a key event during Myc-
induced lymphomagenesis (Strasser et al. 1990; Schmitt
et al. 2002), and genes that suppress apoptosis, like
eIF4E, Akt, or Bcl-2 can prevent p53 loss in lymphomas
derived from p53+/− cells (Schmitt et al. 2002; Wendel et
al. 2004). The observation that activated MNK1 also pro-
duces rapid tumors with a low apoptotic rate suggests
that eIF4E phosphorylation attenuates apoptosis. To test
this, we introduced mutant forms of eIF4E or Mnk1 into
Eµ-Myc/p53+/− HSCs and determined whether the result-
ing tumors retained the wild-type p53 allele. Here, only
tumors expressing the S209D mutant or activated
MNK1—but not those expressing S209A—retained the
wild-type p53 allele (three out of three for eIF4E S209D,
and two out of three Mnk1) (Fig. 2C).
In parallel, we tested the ability of activated (T332D)
and dominant-negative (T2A2) MNK1 and different
eIF4E mutants to oppose c-Myc-induced apoptosis in
mouse embryo fibroblasts (MEFs) (Evan et al. 1992).
MEFs coinfected with c-Myc and eIF4E, its S209D mu-
tant, or activated Mnk1 were resistant to apoptosis; in
contrast, cells expressing vector alone, Mnk (T2A2), or
the S209A mutant alleles of eIF4E remained sensitive
(Fig. 2D). Thus, the oncogenic function of Mnk1 and
eIF4E correlates with their ability to attenuate apoptosis
in vitro and in vivo.
Our results linking Mnk to oncogenesis are surprising
given that mice deficient in Mnk kinase develop nor-
mally (Ueda et al. 2004). Next, we tested whether MNK
inhibition would sensitize cells to apoptosis in vitro or
inhibit tumor expansion in vivo. MEFs derived from
Mnk1/2 double-knockout (DKO) mice were transduced
with Myc and examined for viability after serum deple-
tion (Evan et al. 1992). Mnk1/2 DKO MEFs expressing
Myc were hypersensitized to apoptosis (Fig. 3A,
P < 0.0001) in a manner was reversed by reintroduction
Figure 1. eIF4E correlates with oncogenicity in vivo. (A) The eIF4
mutants used in this study. (B) Kaplan-Meier plot showing tumor
onset data for mice reconstituted with Eµ-Myc HSCs expressing
eIF4E (red, n = 45), or mutant alleles (W56A: green, n = 23; W73F:
blue, n = 9; S209A: violet, n = 29; S209D: orange, n = 10) and vector
(black, n = 61, includes historic controls). Numbers in brackets in-
dicate the percentage of GFP-expressing tumors. (C) Fluorescence
imaging of an Eµ-Myc/eIF4E tumor-bearing mouse (left), cerebral
tumor (top right), and isolated tumors (bottom right).
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of the activated Mnk1 allele (T332D). However, in con-
trast to wild-type cells, Mnk1/2 DKO cells overexpress-
ing both eIF4E and the S209A mutant remained hyper-
sensitive to apoptosis (Fig. 3B).
We also examined tumor expansion of lymphoma cells
expressing a dominant-negative MNK1 kinase mutant
capable of attenuating eIF4e phosphorylation (T197A/
T202A, denoted T2A2; see Supplementary Fig. 3;
Waskiewicz et al. 1999). A subset of tumor cells was
transduced with a Mnk-expressing MSCV-IRES-GFP-
based vector and the mixed population transplanted into
recipient animals. In this assay, an increase or decrease
in GFP indicates that cells expressing the transgene
have a selective advantage or disadvantage compared
with controls, respectively. The assay was performed in
Eµ-Myc/Arf−/− and Eµ-Myc/Tsc2−/− tumor cells, since
TSC2-null lymphomas activate the mTOR pathway and
ARF-null lymphomas do not (A. Malina and J. Pelletier,
unpubl.) (Wendel et al. 2006).
The impact of Mnk inhibition was genotype depen-
dent. The activated Mnk1 (T332D) conferred an advan-
tage in vivo, and cells of either genotype expressing this
mutant were enriched during tumor formation (Fig. 3C,
top panels). By contrast, while the Mnk1 (T2A2) mutant
had minimal effect in Arf−/− lymphoma cells, it dramati-
cally inhibited the proliferation of Tsc2−/− cells, such
that T2A2-expressing lymphoma cells were almost com-
pletely depleted from the population during lymphoma
expansion (Fig. 3C, bottom panels). Thus, Mnk kinase
inhibition appears to selectively inhibit tumor cells with
deregulated translational control.
One potential anti-apoptotic target of phosphorylated
eIF4E is Mcl-1, which is preferentially translated in some
cancer cells with defects in RAS/PI3K signaling (Raja-
sekhar et al. 2003; Adams and Cooper 2007) and whose
translation is reduced in human leukemia cells follow-
ing pharmacologic inhibition of MAPK signaling (Rah-
mani et al. 2005). Accordingly, MNK1-expressing tu-
mors expressed elevated levels of eIF4E phosphorylation
and Mcl-1 protein (Fig. 4A). Acute expression of eIF4E
and MNK1, but not eIF4E S209A, in MEFs also increased
Mcl-1 protein levels (Fig. 4B), whereas the dominant-
negative MNK1 (T2A2) had the opposite effect (Fig. 4C).
The ability of eIF4E or MNK1 to increase Mcl-1 protein
was partly due to translation, since cells expressing these
genes contain more Mcl-1 mRNA in the polysome frac-
tion compared with controls, which remained un-
changed in total mRNA (Fig. 4D,E). Finally, MCL-1 dra-
matically accelerated lymphomagenesis in the Eµ-Myc
model (Fig. 4F). While MCL-1 expression in the resulting
tumors was significantly higher than those expressing
eIF4E or Mnk1 (data not shown), these data collectively
Figure 3. Activated MNK1 opposes Myc-induced apoptosis. (A)
Phase contrast of c-myc-expressing wild-type (WT) and Mnk1/2
DKO (Mnk1/2 DKO) MEFs 16 h after serum withdrawal. Mean
and standard deviation (n = 3) of cell viability are indicated. (B) Vi-
ability of Mnk1/2 DKO MEFs expressing c-Myc and vector or the
indicated genes following serum withdrawal for 12 h. (*) P < 0.05;
(**) P < 0.01. (C) Flow cytometry of tumor cell populations from
Eµ-Myc/Arf−/− or Eµ-Myc/TSC2−/− lymphomas, partially transduced
retroviruses coexpressing GFP, and constitutively active Mnk1
(T332D, top panels) or dominant-negative Mnk1 (T2A2, bottom
panels) before (Input) and after (Tumor) lymphoma expansion in
vivo.
Figure 2. Activated MNK1 promotes lymphomagenesis. (A)
Kaplan-Meier analysis of mice reconstituted with Eµ-Myc HSCs ex-
pressing an activated mutant Mnk1 (T332D) (green, n = 14), domi-
nant-negative Mnk1 (T2A2) (blue, n = 10), or control (black, n = 61,
controls as in Fig. 1). Numbers in brackets indicate the percentage of
GFP-expressing tumors. (B) Representative micrographs of the indi-
cated lymphomas stained as indicated. (C) Allele-specific PCR to
detect the wild-type p53 (WT) and mutant allele (M) in tumors de-
rived from Eµ-Myc/p53+/− HSCs transduced with the S209A and
S209D mutants of eIF4E or an activated Mnk1 (T332D), and FACS
sorted for GFP-expressing cells. (D) Viability of wild-type MEFs ex-
pressing c-Myc and empty vector or the indicated alleles and with-
drawn from serum for 24 h. (*) Denotes P ∼ 0.02 compared with
vector.
Wendel et al.
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indicate that Mcl-1 is one target of phosphorylated eIF4E
during oncogenesis.
To determine whether eIF4E phosphorylation corre-
lates with MCL-1 in human lymphomas, we analyzed
tissue microarrays (TMAs) constructed from 77 patient
samples of diffuse large B-cell lymphoma (DLBCL) (Fig.
5A,B). Notably, all 13 cases that were positive for phos-
pho-eIF4E stained positive for MCL-1 protein and,
among the 55 cases that were negative for eIF4E phos-
phorylation, 18 were negative and 37 were positive for
MCL-1. Thus, eIF4E phosphorylation correlated with
MCL-1 expression (P = 0.02 by Fisher’s exact test) in
DLBCL, although other mechanisms must also contrib-
ute to the elevated levels of MCL-1 observed in this tu-
mor type. Similarly, in a small cohort of Burkitt lym-
phoma samples (n = 8), all six cases that stained positive
for phosphorylated eIF4E were also positive for MCL-1
compared with reactive lymph nodes (Fig. 5C). These
clinical data are consistent with the genetic interactions
observed in the mouse.
These results provide insights into how translational
deregulation promotes tumorigenesis and have therapeu-
tic implications. For example, the biological roles and
mechanism of action of eIF4E phosphorylation on Ser
209 have been controversial, leading to speculation that
this event is not important for translational control in
mammalian systems (Waskiewicz et al. 1997; Scheper
and Proud 2002). However, while eIF4E phosphorylation
is dispensable for mouse development (Ueda et al. 2004),
our studies indicate that it plays a crucial role during
tumorigenesis. Thus, eIF4E’s oncogenic activity corre-
lates with its ability to activate translation and become
phosphorylated on Ser 20, and constitutively activated
Mnk1, a Ser 209 kinase, promotes tumorigenesis in a
manner similar to eIF4E. Furthermore, a dominant-nega-
tive MNK1 mutant prevents eIF4E phosphorylation and
inhibits the proliferation of tumor cells driven by muta-
tions that deregulate translation. Consistent with our
findings, the S209A cannot transform NIH 3T3 cells in
vitro (Topisirovic et al. 2004). Still, it is unlikely that the
organismal role of eIF4E phosphorylation is to promote
Figure 5. eIF4E phosphorylation correlates with MCL-1 expression
in human lymphoma. (A,B) Representative photographs (low and
high power) of tissue arrays constructed from human DLBCL and
probed for phosphorylated eIF4E and MCL-1. The photographs illus-
trate DLBCL staining either negative (A) or positive (B) for both
phosphorylated eIF4E and MCL1. (C) Photomicrographs of Burkitt
lymphoma samples stained for phosphorylated eIF4E and MCL-1.
Figure 4. Mcl-1 contributes to the oncogenic effect of eIF4E phos-
phorylation. (A) Immunoblotting of control and Mnk1 (Mnk1/
T332D)-expressing lymphomas. (B) Immunoblotting of MEFs trans-
duced with vector, eIF4E (eIF4E), the S209a mutant of eIF4E
(S209A), and Mnk1 (Mnk1/T332D), or Mnk1/2 DKO MEFs. (C) Im-
munoblotting of 3T3 fibroblasts transduced with vector, dominant-
negative Mnk1 (Mnk1/T2A2) or active Mnk1 (T332D) with (+) or
without (−) serum. (D) Semiquantitative RT–PCR of Mcl-1 and
-Actin (Actin) mRNA in total RNA or polysomal RNA collected
from MEFs transduced with vector, eIF4E (eIF4E), or Mnk1 (Mnk1/
T332D); dilutions (1:1 to 1:100) were to enhance quantification. (E)
Quantitative real-time RT–PCR of Mcl-1 normalized to -Actin
from cDNA samples prepared from MEFs transduced with vector,
eIF4E, or active Mnk1 (Mnk1/T332D). Shown is a “relative quanti-
fication” whereby the Mcl-1 expression in triplicates of the total and
polysome samples from vector-transduced cells is set to “1” and
compared with the total and polysome fraction from cells expressing
either eIF4E or Mnk1 (T332D). (F) Kaplan-Meier analysis of tumor
latency of mice reconstituted with Eµ-Myc HSCs transduced with
vector (black, n = 61, as in Fig. 1) or Mcl-1 (red, n = 5).
eIF4E in tumorigenesis
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tumorigenesis, but perhaps instead acts to enhance
translation under circumstances of proliferation or cell
stress.
In the Eµ-Myc model, phosphorylated eIF4E appears to
promote tumorigenesis mainly by suppressing apoptosis,
although how this occurs at the biochemical level re-
mains to be fully elucidated. Most, but not all, studies
suggest that phosphorylation has a positive effect on cap-
dependent translation (Scheper and Proud 2002). Mcl-1,
which is encoded by a message containing a structured
5UTR, is specifically affected by the state of eIF4E phos-
phorylation in our model. Accordingly, high levels of
phosphorylated eIF4E and MCL-1 occur together in hu-
man lymphomas. Thus, while MCL-1 may be regulated
at additional levels (Le Gouill et al. 2004), its enhanced
translation likely contributes to eIF4E-mediated onco-
genesis.
The roles of the MNK kinases have remained elusive
owing to the lack of biological readouts for their activity
and a phenotype in the knockout mice (Ueda et al. 2004).
We see that a constitutively activated MNK1 can be a
potent oncogene in vivo. Of note, the similar onset and
pathology of Mnk1- and eIF4E-expressing tumors, the
inability of the MNK target site eIF4E mutant (S209A) to
be oncogenic, and the shared ability of eIF4E and acti-
vated MNK1 to up-regulate MCL-1 all suggest that the
oncogenic impact of MNK kinases involves targeting
eIF4E, although it remains possible that nontranslational
targets also play a role. Although sporadic mutations in
Mnk1 or Mnk2 have not been observed, our studies raise
the possibility these enzymes may mediate oncogenic
signals in human cancers.
The fact that eIF4E acts at a convergence point of two
crucial signaling pathways altered in cancer cells makes
it an intriguing therapeutic target. Although targeting
the translation initiation apparatus might produce sub-
stantial toxicity, our observation that eIF4E phosphory-
lation is important for tumorigenesis and previous work
suggesting that it is dispensable for organismal viability
suggests that inhibiting this event would have selective
anti-tumor activity. Consistent with this idea and ex-
tending it further, our limited analysis to date suggests
that the anti-proliferative effects of MNK1 kinase inhi-
bition are restricted to tumors with deregulated transla-
tional control. Interestingly, small molecule inhibitors
of the MNK kinases have been produced but are not be-
ing developed and, in our hands, were unable to prevent
MNK-induced phosphorylation of eIF4E in vivo (A. Ma-
lina and J. Pelletier, unpubl.). By contrast, inhibitors of
mTOR are in clinical trials, although their activity is
limited, in part, by activation of AKT/PKB through a
feedback mechanism involving S6 kinase (Sun et al.
2005). Targeting eIF4E downstream from mTOR—for ex-
ample, via inhibition of MNK kinases—might circum-
vent feedback activation and present a therapeutic alter-
native.
Materials and methods
Animal studies
Lymphomas were generated and analyzed as described (Schmitt et al.
2002). The retroviruses used to produce tumors were based on MSCV-
IRES-GFP (MIG) and expressed cDNAs encoding the eIF4E mutants
W56A, W73A, S209A, and S209D, and the Mnk alleles T332D and T2A2.
p53 loss of heterozygosity (LOH) was determined by allele-specific PCR
of FACS-purified tumor cells (Wendel et al. 2004). For competition ex-
periments, short-term lymphoma cultures were transduced with GFP-
expressing retroviral vectors and the mixed populations were trans-
planted by tail-vein injection into nontransgenic female C57BL/6 ani-
mals. Tumors were then harvested and GFP expression was determined
by flow cytometry (Wendel et al. 2004).
Histopathology
Preparation of samples, H&E stain, and detection of antibody stains was
described (Wendel et al. 2004). Antibodies were against phosphorylated
ribosomal S6 protein (Cell Signaling #2215) and phosphorylated eIF4E
(Cell Signaling #9714). TUNEL was performed using a published protocol
(McCurrach and Lowe 2001).
TMA analysis
The study cohort comprised 77 DLBCL collected and diagnosed at first
evaluation at MSKCC and approved by the MSKCC IRB. TMAs were
constructed as described previously (Maeda et al. 2005) and stained with
antibodies against phosphorylated eIF4E (Cell Signaling #9741, 1:10) and
Mcl1 (Cell Signaling #4572, 1:250). Positivity was defined as at least 30%
of tumor cells stained for the probed antigen.
Western blot analysis
Immunoblots were performed as described (Wendel et al. 2004) using
antibodies against phosphorylated Mnk1 (Cell Signaling #2111, 1:1000),
total and phosphorylated eIF4E (both 1:1000, Cell Signaling #9742 and
#9741), total and phosphorylated ribosomal S6 (Cell Signaling #2215,
1:1000), Mcl-1 (Abcam, ab32087-100, 1:1000), Tubulin (Sigma, B-5-1-2,
1:5000), and anti-HA (Roche 12013819, 1:5000).
Flow cytometry
Tumor cell suspensions were stained with the indicated antibodies
(PharMingen and CalTag) conjugated with phycoerythrin (PE), Tri-Color
(TC), or biotin, developed with streptavidin–allophycocyanin (PharMin-
gen) and analyzed with FACSCalibur (Becton Dickinson).
Cell culture and viability
Primary MEFs of wild-type and Mnk1/2 DKO were cultured and analyzed
as described (McCurrach and Lowe 2001). For apoptosis assays, MEFs
were transduced with pBabe-Myc, selected with puromcin, and subjected
to serum withdrawal for 12–24 h; viability was determined by trypan
blue stain.
Polysome fractionation
As described in detail in Xi et al. (2004), cells were treated with cyclo-
heximide before harvesting and lysing. The nuclei were pelleted and the
ribosomal components were separated from the soluble fraction by ul-
tracentrifugation. RNA was isolated using Trizol (Invitrogen) and cDNA
synthesis was performed using the SuperScript III kit (Invitrogen). RT–
PCR primers were Mcl1F, AGCCTGACTTCCCAGCTCAC; Mcl1R,
GCACTCAGACCACATGCTTC; ActinF, AAGCTAACCGGGAGAA
GATG; and ActinR, GTAGTCAGTGAGGTCGCGAC.
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